Search

Your search keyword '"Erickson, Beth"' showing total 172 results
Start Over Author "Erickson, Beth" Publication Year Range Last 3 years
172 results on '"Erickson, Beth"'

1. Patterns of Locoregional Pancreatic Cancer Recurrence After Total Neoadjuvant Therapy and Implications on Optimal Neoadjuvant Radiation Treatment Volumes

Author

Beltran Ponce, Sara. E., Small, Christina J., Ahmad, Talha, Patel, Kishan, Tsai, Susan, Kamgar, Mandana, George, Ben, Kharofa, Jordan R., Saeed, Hina, Dua, Kulwinder S., Clarke, Callisia N., Aldakkak, Mohammed, Evans, Douglas B., Christians, Kathleen, Paulson, Eric S., Erickson, Beth, and Hall, William A.

Published
2025
Full Text
View/download PDF

3. Treatment planning for MR-guided SBRT of pancreatic tumors on a 1.5 T MR-Linac: A global consensus protocol

Author

Grimbergen, Guus, Eijkelenkamp, Hidde, Snoeren, Louk M.W., Bahij, Rana, Bernchou, Uffe, van der Bijl, Erik, Heerkens, Hanne D., Binda, Shawn, Ng, Sylvia S.W., Bouchart, Christelle, Paquier, Zelda, Brown, Kerryn, Khor, Richard, Chuter, Robert, Freear, Linnéa, Dunlop, Alex, Mitchell, Robert Adam, Erickson, Beth A., Hall, William A., Godoy Scripes, Paola, Tyagi, Neelam, de Leon, Jeremiah, Tran, Charles, Oh, Seungjong, Renz, Paul, Shessel, Andrea, Taylor, Edward, Intven, Martijn P.W., and Meijer, Gert J.

Published
2024
Full Text
View/download PDF

5. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma

Author

George, Ben, Kudryashova, Olga, Kravets, Andrey, Thalji, Samih, Malarkannan, Subramaniam, Kurzrock, Razelle, Chernyavskaya, Ekatherina, Gusakova, Mariia, Kravchenko, Dmitry, Tychinin, Dmitry, Savin, Egor, Alekseeva, Lolita, Butusova, Anna, Bagaev, Aleksander, Shin, Nara, Brown, Jessica H., Sethi, Isha, Wang, Dandan, Taylor, Bradley, McFall, Thomas, Kamgar, Mandana, Hall, William A., Erickson, Beth, Christians, Kathleen K., Evans, Douglas B., and Tsai, Susan

Published
2024
Full Text
View/download PDF

6. Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians.

Author

Hall, William, Paulson, Eric, Li, X, Erickson, Beth, Schultz, Christopher, Tree, Alison, Awan, Musaddiq, McDonald, Brigid, Salzillo, Travis, Glide-Hurst, Carri, Kishan, Amar, Fuller, Clifton, and Low, Daniel

Subjects
0.35 Tesla MR Guidance, 1.5 Tesla MR Guidance, RT adaption, Unity, ViewRay, adaptive image guidance, adaptive radiation therapy, magnetic resonance (MR)-guided radiation, personalized radiation therapy, History, 20th Century, History, 21st Century, Humans, Magnetic Resonance Imaging, Interventional, Neoplasms, Particle Accelerators, Radiation Oncology, Radiotherapy Planning, Computer-Assisted
Abstract

Radiation therapy (RT) continues to play an important role in the treatment of cancer. Adaptive RT (ART) is a novel method through which RT treatments are evolving. With the ART approach, computed tomography or magnetic resonance (MR) images are obtained as part of the treatment delivery process. This enables the adaptation of the irradiated volume to account for changes in organ and/or tumor position, movement, size, or shape that may occur over the course of treatment. The advantages and challenges of ART maybe somewhat abstract to oncologists and clinicians outside of the specialty of radiation oncology. ART is positioned to affect many different types of cancer. There is a wide spectrum of hypothesized benefits, from small toxicity improvements to meaningful gains in overall survival. The use and application of this novel technology should be understood by the oncologic community at large, such that it can be appropriately contextualized within the landscape of cancer therapies. Likewise, the need to test these advances is pressing. MR-guided ART (MRgART) is an emerging, extended modality of ART that expands upon and further advances the capabilities of ART. MRgART presents unique opportunities to iteratively improve adaptive image guidance. However, although the MRgART adaptive process advances ART to previously unattained levels, it can be more expensive, time-consuming, and complex. In this review, the authors present an overview for clinicians describing the process of ART and specifically MRgART.

Published
2022

8. NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation Therapy

Author

Sanford, Nina N., Narang, Amol K., Aguilera, Todd A., Bassetti, Michael F., Chuong, Michael D., Erickson, Beth A., Goodman, Karyn A., Herman, Joseph M., Intven, Martijn, Kilcoyne, Aoife, Kim, Hyun, Paulson, Eric, Reyngold, Marsha, Tsai, Susan, Tchelebi, Leila T., Tuli, Richard, Versteijne, Eva, Wei, Alice C., Wo, Jennifer Y., Zhang, Ying, Hong, Theodore S., and Hall, William A.

Published
2024
Full Text
View/download PDF

9. Consensus Guidelines for Delineation of Clinical Target Volumes for Intensity Modulated Radiation Therapy for Intact Cervical Cancer: An Update

Author

Fields, Emma C., Bosch, Walter R., Albuquerque, Kevin V., Bhatia, Rohini, Chino, Junzo, Dyer, Brandon, Erickson, Beth, Fabian, Denise, Gaffney, David, Glaser, Scott, Han, Kathy, Hathout, Lara, Hsu, I-Chow, Jegadeesh, Naresh, Kahn, Jenna, Kidd, Elizabeth, Klopp, Ann, Leung, Eric, Lin, Lilie, Ludwig, Michelle, Ma, Tianjun, Mell, Loren, Mayadev, Jyoti, Petersen, Ivy, Portelance, Lorraine, Rash, Dominique, Taunk, Neil, Viswanathan, Akila, Wolfson, Aaron, Yashar, Catheryn, Yeung, Anamaria, Yoshida, Emi, and Fisher, Christine M.

Published
2024
Full Text
View/download PDF

19. Changes in Daily Apparent Diffusion Coefficient on Fully Quantitative Magnetic Resonance Imaging Correlate With Established Genomic Pathways of Radiation Sensitivity and Reveal Novel Biologic Associations

Author

Hall, William A., primary, Mathison, Angela J., additional, DeVoe, Elias, additional, Tschannen, Michael, additional, Wendt-Andrae, Jaime, additional, Straza, Michael, additional, Awan, Musaddiq, additional, Puckett, Lindsay L., additional, Lawton, Colleen A.F., additional, Schultz, Christopher, additional, Urrutia, Raul, additional, Kerns, Sarah, additional, Torres-Roca, Javier F., additional, Li, X. Allen, additional, Erickson, Beth, additional, Nevalainen, Marja T., additional, Zimmermann, Michael T., additional, and Paulson, Eric, additional

Published
2024
Full Text
View/download PDF

20. Safety and Tolerability of Online Adaptive High-Field Magnetic Resonance–Guided Radiotherapy

Author

Westerhoff, Jasmijn M., primary, Daamen, Lois A., additional, Christodouleas, John P., additional, Blezer, Erwin L. A., additional, Choudhury, Ananya, additional, Westley, Rosalyne L., additional, Erickson, Beth A., additional, Fuller, Clifton D., additional, Hafeez, Shaista, additional, van der Heide, Uulke A., additional, Intven, Martijn P. W., additional, Kirby, Anna M., additional, Lalondrelle, Susan, additional, Minsky, Bruce D., additional, Mook, Stella, additional, Nowee, Marlies E., additional, Marijnen, Corrie A. M., additional, Orrling, Kristina M., additional, Sahgal, Arjun, additional, Schultz, Christopher J., additional, Faivre-Finn, Corinne, additional, Tersteeg, Robbert J. H. A., additional, Tree, Alison C., additional, Tseng, Chia-Lin, additional, Schytte, Tine, additional, Silk, Dustin M., additional, Eggert, Dave, additional, Luzzara, Marco, additional, van der Voort van Zyp, Jochem R. N., additional, Verkooijen, Helena M., additional, and Hall, William A., additional

Published
2024
Full Text
View/download PDF

22. Erratum to: Fields EC, Erickson B, Hubbard A, Chino J, Small C, Weiner A, Petereit D, Mayadev JS, Yashar CM, Joyner M. Tipping the Balance: Adding Resources for Cervical Cancer Brachytherapy. Int J Radiat Oncol Biol Phys 2023;117:1138–1142

Author

Fields, Emma C., primary, Erickson, Beth, additional, Hubbard, Anne, additional, Chino, Junzo, additional, Small, Christina, additional, Weiner, Ashley, additional, Petereit, Daniel, additional, Mayadev, Jyoti S., additional, Yashar, Catheryn M., additional, and Joyner, Melissa, additional

Published
2024
Full Text
View/download PDF

23. Treatment planning for MR-guided SBRT of pancreatic tumors on a 1.5 T MR-Linac: A global consensus protocol

Author

Cancer, Fysica Radiotherapie Research, Onderzoek Radiotherapie, MS Radiotherapie, Klinische Fysica RT, Grimbergen, Guus, Eijkelenkamp, Hidde, Snoeren, Louk M.W., Bahij, Rana, Bernchou, Uffe, van der Bijl, Erik, Heerkens, Hanne D., Binda, Shawn, Ng, Sylvia S.W., Bouchart, Christelle, Paquier, Zelda, Brown, Kerryn, Khor, Richard, Chuter, Robert, Freear, Linnéa, Dunlop, Alex, Mitchell, Robert Adam, Erickson, Beth A., Hall, William A., Godoy Scripes, Paola, Tyagi, Neelam, de Leon, Jeremiah, Tran, Charles, Oh, Seungjong, Renz, Paul, Shessel, Andrea, Taylor, Edward, Intven, Martijn P.W., Meijer, Gert J., Cancer, Fysica Radiotherapie Research, Onderzoek Radiotherapie, MS Radiotherapie, Klinische Fysica RT, Grimbergen, Guus, Eijkelenkamp, Hidde, Snoeren, Louk M.W., Bahij, Rana, Bernchou, Uffe, van der Bijl, Erik, Heerkens, Hanne D., Binda, Shawn, Ng, Sylvia S.W., Bouchart, Christelle, Paquier, Zelda, Brown, Kerryn, Khor, Richard, Chuter, Robert, Freear, Linnéa, Dunlop, Alex, Mitchell, Robert Adam, Erickson, Beth A., Hall, William A., Godoy Scripes, Paola, Tyagi, Neelam, de Leon, Jeremiah, Tran, Charles, Oh, Seungjong, Renz, Paul, Shessel, Andrea, Taylor, Edward, Intven, Martijn P.W., and Meijer, Gert J.

Published
2024

24. Safety and Tolerability of Online Adaptive High-Field Magnetic Resonance-Guided Radiotherapy

Author

Trialbureau Beeld, Cancer, Brain, MS Radiotherapie, Westerhoff, Jasmijn M., Daamen, Lois A., Christodouleas, John P., Blezer, Erwin L.A., Choudhury, Ananya, Westley, Rosalyne L., Erickson, Beth A., Fuller, Clifton D., Hafeez, Shaista, Van Der Heide, Uulke A., Intven, Martijn P.W., Kirby, Anna M., Lalondrelle, Susan, Minsky, Bruce D., Mook, Stella, Nowee, Marlies E., Marijnen, Corrie A.M., Orrling, Kristina M., Sahgal, Arjun, Schultz, Christopher J., Faivre-Finn, Corinne, Tersteeg, Robbert J.H.A., Tree, Alison C., Tseng, Chia-Lin, Schytte, Tine, Silk, Dustin M., Eggert, Dave, Luzzara, Marco, Van Der Voort Van Zyp, Jochem R.N., Verkooijen, Helena M., Hall, William A., Trialbureau Beeld, Cancer, Brain, MS Radiotherapie, Westerhoff, Jasmijn M., Daamen, Lois A., Christodouleas, John P., Blezer, Erwin L.A., Choudhury, Ananya, Westley, Rosalyne L., Erickson, Beth A., Fuller, Clifton D., Hafeez, Shaista, Van Der Heide, Uulke A., Intven, Martijn P.W., Kirby, Anna M., Lalondrelle, Susan, Minsky, Bruce D., Mook, Stella, Nowee, Marlies E., Marijnen, Corrie A.M., Orrling, Kristina M., Sahgal, Arjun, Schultz, Christopher J., Faivre-Finn, Corinne, Tersteeg, Robbert J.H.A., Tree, Alison C., Tseng, Chia-Lin, Schytte, Tine, Silk, Dustin M., Eggert, Dave, Luzzara, Marco, Van Der Voort Van Zyp, Jochem R.N., Verkooijen, Helena M., and Hall, William A.

Published
2024

25. Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series.

Author

Mehdi, Maahum, Szabo, Aniko, Shreenivas, Aditya, Thomas, James P., Tsai, Susan, Christians, Kathleen K., Evans, Douglas B., Clarke, Callisia N., Hall, William A., Erickson, Beth, Ahmed, Gulrayz, Thapa, Bicky, McFall, Thomas, George, Ben, Kurzrock, Razelle, and Kamgar, Mandana

Abstract

Background: KRAS wild-type (WT) pancreatic ductal adenocarcinoma (PDAC) represents a distinct entity with unique biology. The therapeutic impact of matched targeted therapy in these patients in a real-world setting, to date, is less established. Objectives: The aim of our study was to review our institutional database to identify the prevalence of actionable genomic alterations in patients with KRAS -WT tumors and to evaluate the therapeutic impact of matched targeted therapy in these patients. Design: We reviewed electronic medical records of patients with KRAS-WT PDAC and advanced disease (n = 14) who underwent clinical-grade tissue ± liquid next-generation sequencing (315–648 genes for tissue) between years 2015 and 2021. Methods: Demographic and disease characteristics were summarized using descriptive parameters. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method. Results: Of 236 PDAC patients, 14 had advanced/metastatic disease with KRAS-WT tumors. Median age at diagnosis was 66 years. There was a high frequency of potentially actionable genomic alterations, including three (21%) with BRAF alterations, two (14%) with fusions [ RET-PCM1 and FGFR2-POC1B (N = 1 each)]; and one with a druggable EGFR (EGFR E746_A755delISERD) variant; two other patients had an STK11 and a MUTYH alteration. Five patients were treated with matched targeted therapy, with three having durable benefit: (i) erlotinib for EGFR -altered tumor, followed by osimertinib/capmatinib when MET amplification emerged (first-line therapy); (ii) pralsetinib for RET fusion (fifth line); and (iii) dabrafenib/trametinib for BRAF N486_P490del (third line). Duration of time on chemotherapy-free matched targeted therapy for these patients was 17+, 11, and 18+ months, respectively. Conclusion: Sustained therapeutic benefit can be achieved in a real-world setting in a subset of patients with advanced/metastatic KRAS-WT PDAC treated with chemotherapy-free matched targeted agents. Prospective studies are warranted. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy

Author

de Ortiz de Choudens, Saryleine, primary, Visotcky, Alexis, additional, Banerjee, Anjishnu, additional, Aldakkak, Mohammed, additional, Tsai, Susan, additional, Evans, Douglas B., additional, Christians, Kathleen K., additional, Clarke, Callisia N., additional, George, Ben, additional, Shreenivas, Aditya, additional, Kamgar, Mandana, additional, Chakrabarti, Sakti, additional, Dua, Kulwinder S., additional, Khan, Abdul Haq, additional, Madhavan, Srivats, additional, Erickson, Beth A., additional, and Hall, William A., additional

Published
2023
Full Text
View/download PDF

28. Clinical outcomes after online adaptive MR-guided stereotactic body radiotherapy for pancreatic tumors on a 1.5 T MR-linac

Author

Eijkelenkamp, Hidde, primary, Grimbergen, Guus, additional, Daamen, Lois A., additional, Heerkens, Hanne D., additional, van de Ven, Saskia, additional, Mook, Stella, additional, Meijer, Gert J., additional, Molenaar, Izaak Q., additional, van Santvoort, Hjalmar C., additional, Paulson, Eric, additional, Erickson, Beth Ann, additional, Verkooijen, Helena M., additional, Hall, William Adrian, additional, and Intven, Martijn P. W., additional

Published
2023
Full Text
View/download PDF

29. Stereotactic Body Radiation Therapy for Gynecologic Malignancies: A Case-Based Radiosurgery Society Practice Review

Author

Ladbury, Colton, primary, Sueyoshi, Mark H., additional, Brovold, Nellie M., additional, Kumar, Ritesh, additional, Andraos, Therese Y., additional, Gogineni, Emile, additional, Kim, Minsun, additional, Klopp, Ann, additional, Albuquerque, Kevin, additional, Kunos, Charles, additional, Leung, Eric, additional, Mantz, Constantine, additional, Biswas, Tithi, additional, Beriwal, Sushil, additional, Small, William, additional, Erickson, Beth, additional, Gaffney, David, additional, Lo, Simon S., additional, and Viswanathan, Akila N., additional

Published
2023
Full Text
View/download PDF

31. Clinical outcomes after online adaptive MR-guided stereotactic body radiotherapy for pancreatic tumors on a 1.5 T MR-linac

Author

Cancer, Onderzoek Radiotherapie, Fysica Radiotherapie Research, MS CGO, Trialbureau Beeld, Arts-assistenten Radiotherapie, MS Radiotherapie, Klinische Fysica RT, MS HOD, Eijkelenkamp, Hidde, Grimbergen, Guus, Daamen, Lois A, Heerkens, Hanne D, van de Ven, Saskia, Mook, Stella, Meijer, Gert J, Molenaar, Izaak Q, van Santvoort, Hjalmar C, Paulson, Eric, Erickson, Beth Ann, Verkooijen, Helena M, Hall, William Adrian, Intven, Martijn P W, Cancer, Onderzoek Radiotherapie, Fysica Radiotherapie Research, MS CGO, Trialbureau Beeld, Arts-assistenten Radiotherapie, MS Radiotherapie, Klinische Fysica RT, MS HOD, Eijkelenkamp, Hidde, Grimbergen, Guus, Daamen, Lois A, Heerkens, Hanne D, van de Ven, Saskia, Mook, Stella, Meijer, Gert J, Molenaar, Izaak Q, van Santvoort, Hjalmar C, Paulson, Eric, Erickson, Beth Ann, Verkooijen, Helena M, Hall, William Adrian, and Intven, Martijn P W

Published
2023

32. Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy.

Author

de Ortiz de Choudens, Saryleine, Visotcky, Alexis, Banerjee, Anjishnu, Aldakkak, Mohammed, Tsai, Susan, Evans, Douglas B., Christians, Kathleen K., Clarke, Callisia N., George, Ben, Shreenivas, Aditya, Kamgar, Mandana, Chakrabarti, Sakti, Dua, Kulwinder S., Khan, Abdul Haq, Madhavan, Srivats, Erickson, Beth A., and Hall, William A.

Subjects
CANCER chemotherapy, METASTASIS, LOG-rank test, ADENOCARCINOMA, IMAGE segmentation, NON-communicable diseases
Abstract

Purpose/Objectives: Most patients with pancreatic adenocarcinoma (PDAC) will present with distant metastatic disease at diagnosis. We sought to identify clinical characteristics associated with prolonged overall survival (OS) in patients presenting with metastatic PDAC. Materials/Methods: Patients presenting with metastatic PDAC that received treatment at our institution with FOLFIRINOX or gemcitabine-based chemotherapies between August 1, 2011 and September 1, 2017 were included in the study. Metastatic disease burden was comprehensively characterized radiologically via individual diagnostic imaging segmentation. Landmark analysis was performed at 18months, and survival curves were estimated using the Kaplan– Meier method and compared between groups via the log-rank test. ECOG and Charlson Comorbidity Index (CCI) were calculated for all patients. Results: 121 patients were included with a median age of 62 years (37–86), 40% were female, 25% had ECOG 0 at presentation. Of the 121 patients included, 33% (n=41) were alive at 12months and 25% (n=31) were alive at 18months. Landmark analysis demonstrated a significant difference between patients surviving <18months and ≥18months regarding the presence of lung only metastases (36% vs. 16%, p=0.04), number of organs with metastases (≥2 vs. 1, p=0.04), and disease volume (mean of 19.1 cc vs. 1.4 cc, p=0.04). At Year 1, predictors for improved OS included ECOG status at diagnosis (ECOG 0 vs. ECOG 1, p=0.04), metastatic disease volume at diagnosis (≤0.1 cc vs. >60 cc, p=0.004), metastasis only in the liver (p=0.04), and normalization of CA 19-9 (p<0.001). At Year 2, the only predictor of improved OS was normalization of the CA 19-9 (p=0.03). In those patients that normalized their CA 19-9, median overall survival was 16months. Conclusions: In this exploratory analysis normalization of CA-19-9 or volumetric metastatic disease burden less than 0.2 cc demonstrated a remarkable OS, similar to that of patients with non-metastatic disease. These metrics are useful for counseling patients and identifying cohorts that may be optimal for trials exploring metastatic and/or local tumor-directed interventions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Evolution in the Presence & Evidence Category of Radiation Therapy Treatment Recommendations in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

Author

Conger, Rachael L., primary, Mora, Javier, additional, Straza, Michael W., additional, Erickson, Beth A., additional, Lawton, Colleen A.F., additional, Schultz, Christopher J., additional, Currey, Adam, additional, Bedi, Meena, additional, Siker, Malika L., additional, and Hall, William A., additional

Published
2023
Full Text
View/download PDF

36. GEC-ESTRO (ACROP)–ABS–CBG Consensus Brachytherapy Target Definition Guidelines for Recurrent Endometrial and Cervical Tumors in the Vagina

Author

Kamrava, Mitchell, primary, Leung, Eric, additional, Bachand, Francois, additional, Beriwal, Sushil, additional, Chargari, Cyrus, additional, D'Souza, David, additional, Erickson, Beth, additional, Fokdal, Lars, additional, Han, Kathy, additional, Harkenrider, Matthew, additional, Lin, Lilie, additional, Mahantshetty, Umesh, additional, Nesvacil, Nicole, additional, Ravi, Ananth, additional, Schmid, Max, additional, Vigneault, Eric, additional, Westerveld, Henrike, additional, Yashar, Catheryn, additional, and Nout, Remi, additional

Published
2023
Full Text
View/download PDF

37. A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic adenocarcinoma.

Author

Kamgar, Mandana, primary, Khan, Husain Yar, additional, Aboukameel, Amro, additional, Bannoura, Sahar, additional, Chung, Brian Y., additional, Szabo, Aniko, additional, Li, Yiwei, additional, Al Hallak, Mohammed Najeeb, additional, Philip, Philip Agop, additional, George, Ben, additional, Christians, Kathleen K., additional, Evans, Douglas B., additional, Tsai, Susan, additional, Erickson, Beth, additional, Luther, Sanjeev, additional, Azmi, Asfar S., additional, and Hall, William A., additional

Published
2023
Full Text
View/download PDF

38. Treatment sequencing for patients with localized duodenal and ampullary adenocarcinoma.

Author

Janardan, Abhishek, primary, George, Ben, additional, Ahmed, Gulrayz, additional, Daniel, Sherin, additional, Thapa, Bicky, additional, Mehdi, Maahum, additional, Rein, Lisa, additional, Szabo, Aniko, additional, Erickson, Beth, additional, Hall, William A., additional, Christians, Kathleen K., additional, Tsai, Susan, additional, Evans, Douglas B., additional, and Kamgar, Mandana, additional

Published
2023
Full Text
View/download PDF

40. ATM or CHEK2 alterations: Potential biomarkers of improved outcomes with irinotecan-containing chemotherapy in advanced pancreatic ductal adenocarcinoma.

Author

Mehdi, Maahum, primary, Thapa, Bicky, additional, Szabo, Aniko, additional, Ahmed, Gulrayz, additional, Shreenivas, Aditya V., additional, Thomas, James P., additional, Sriram, Deepika, additional, Evans, Douglas B., additional, Tsai, Susan, additional, Christians, Kathleen K., additional, Erickson, Beth, additional, Hall, William A., additional, McFall, Thomas, additional, Patrick, Steve, additional, George, Ben, additional, Kurzrock, Razelle, additional, and Kamgar, Mandana, additional

Published
2023
Full Text
View/download PDF

41. Atm Or Chek2 Alterations as Potential Biomarkers of Improved Outcomes with Irinotecan: Real-World Analysis of Advanced Pancreatic Ductal Adenocarcinoma

Author

Kamgar, Mandana, primary, Mehdi, Maahum, additional, Thapa, Bicky, additional, Szabo, Aniko, additional, Ahmed, Gulrayz, additional, Shreenivas, Aditya, additional, Thomas, James P., additional, Sriram, Deepika, additional, Evans, Douglas B., additional, Tsai, Susan, additional, Christians, Kathleen K., additional, Erickson, Beth, additional, Hall, William A., additional, Chen, Hui-Zi, additional, Lytle, Nikki, additional, McFall, Thomas, additional, Sarkar, Navonil De, additional, Patrick, Steve, additional, George, Ben, additional, and Kurzrock, Razelle, additional

Published
2023
Full Text
View/download PDF

43. A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma

Author

Saif, Areeba, primary, Verbus, Emily, additional, Erickson, Beth, additional, Kamgar, Mandana, additional, Tsai, Susan, additional, Evans, Douglas, additional, Hernandez, Jonathan M., additional, and Hall, William A., additional

Published
2022
Full Text
View/download PDF

44. ASTRO Supports Access to Evidence-Based Cancer Care for All Patients, Regardless of Pregnancy Status, and Protection for Physicians Recommending and Providing Evidence-Based Care

Author

Jacobson, Geraldine M., primary, Bajaj, Gopal K., additional, Buatti, John M., additional, Dawson, Laura, additional, Deville, Curtiland, additional, Eichler, Thomas J., additional, Erickson, Beth, additional, Ford, Eric, additional, Gibbs, Iris C., additional, Mantz, Constantine, additional, Marples, Brian, additional, Michalski, Jeff M., additional, Sandler, Howard, additional, Smith, Benjamin, additional, Vapiwala, Neha, additional, and Yashar, Catheryn, additional

Published
2022
Full Text
View/download PDF

47. Erratum: “AAPM task group report 303 endorsed by the ABS: MRI implementation in HDR brachytherapy—Considerations from simulation to treatment” https://doi.org/10.1002/mp.15713

Author

Prisciandaro, Joann, primary, Zoberi, Jacqueline (Esthappan), additional, Cohen, Gil'ad, additional, Kim, Yusung, additional, Johnson, Perry, additional, Paulson, Eric, additional, Song, William, additional, Hwang, Ken‐Pin, additional, Erickson, Beth, additional, Beriwal, Sushil, additional, Kirisits, Christian, additional, and Mourtada, Firas, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results